First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study

por Schliemann, Christoph, Gerwing, Mirjam, Heinzow, Hauke, Harrach, Saliha, Schwöppe, Christian, Wildgruber, Moritz, Hansmeier, Anna A., Angenendt, Linus, Berdel, Andrew F., Stalmann, Ursula, Berning, Björna, Kratz-Albers, Karsten, Middelberg-Bisping, Kristina, Wiebe, Stefanie, Albring, Jörn, Wilms, Christian, Hartmann, Wolfgang, Wardelmann, Eva, Krähling, Tobias, Heindel, Walter, Gerss, Joachim, Bormann, Eike, Schmidt, Hartmut, Lenz, Georg, Kessler, Torsten, Mesters, Rolf M., Berdel, Wolfgang E.
Publicado 2020